Investigational drug · Phase 2
Trizepatide
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Diabetes Mellitus, Type 2.
Phase 2Last checked: Nov 19, 2026Latest source record: Sep 21, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
0 still active
All registered trials
2
Any phase or sponsor naming "Trizepatide"
First trial start
2024
Mar 18, 2024
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Trizepatide", any sponsor or status.
Conditions studied
As listed on its trial records.
- Diabetes Mellitus, Type 2
Approved drugs for the same conditions: Cardiovascular and metabolic
Largest trials
Live from ClinicalTrials.gov: studies naming "Trizepatide" as an intervention, largest first.
- A Research Study Comparing How Well Different Doses of the Medicine NN0519-0130 Lower Blood Sugar in People With Type 2 DiabetesPivotal-lookingCompleted
Novo Nordisk A/SNovo Nordisk (NVO)
NCT06326047 · 299 participants · Start Mar 18, 2024 · Primary completion Sep 19, 2025
Drug: NNC0519-0130; Placebo and 1 more · For: Diabetes Mellitus, Type 2
Sites: Chula Vista, California; Fresno, California; Inglewood, California · 110 sites in all
- Effect of Tirzepatide on Cardiovascular and Metabolic Parameters in Obese Adult Patients With Congenital Heart DiseaseNot yet recruiting
University Medical Centre LjubljanaAcademic, hospital or other
NCT07354880 · 30 participants (planned) · Start Jan 20, 2026 · Primary completion Jun 30, 2027
Drug: Treatment with tirzapatide; Treatment with placebo · For: Obesity & Overweight; Adult Congenital Heart Disease
Newest research
PubMed records naming it or its code names, newest first.
- Real-Life Data of Tirzepatide Use to Support Lifestyle Modification in Patients with Metabolic Syndrome.
Śledziona J, Warcho W, Mardas M, et al. · Nutrients 2026
- Hair Loss Associated With Glucagon-Like Peptide-1 (GLP-1) Receptor Agonist Use: A Systematic Review.
Alsuwailem OA, Alanazi R, Almutairi HM, et al. · Cureus 2025
Also in development for Diabetes Mellitus, Type 2
- CagrilintidePhase 320 trials
Novo Nordisk · Obesity, Overweight, Type 2 Diabetes
- RetatrutideLY3437943Phase 316 trials
Eli Lilly · Obesity, Overweight, Type 2 Diabetes
- Maridebart cafraglutideAMG 133Phase 314 trials
Amgen · Obesity, Overweight, Obstructive Sleep Apnea
- EloralintideLY3841136Phase 313 trials
Eli Lilly · Obesity, Overweight, Diabetes Mellitus, Type 2
- HRS9531Phase 313 trials
Fujian Shengdi Pharmaceutical Co., Ltd. · Type 2 Diabetes, Chronic Management of Body Weight, Metabolic Dysfunction-Associated Steatohepatitis (MASH)
- NNC0487-0111Phase 312 trials
Novo Nordisk · Obesity, Overweight, Obstructive Sleep Apnoea
- UBT251Phase 310 trials
The United Bio-Technology (Hengqin) Co., Ltd. · Obesity, Obesity &Amp; Overweight, Diabetes Mellitus, Type 2
- LenbelintideAZD6234Phase 39 trials
AstraZeneca · Obesity or Overweight, Obesity, Overweight
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from Novo Nordisk.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.